(RTTNews) - Zealand Pharma A/S (ZEAL.CO) said Thursday that Boehringer Ingelheim's investigational Survodutide met its co-primary endpoints in the Phase 3 SYNCHRONIZE-2 trial in adults with obesity or overweight and type 2 diabetes.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.